Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;6(4):393.
doi: 10.1002/jcsm.12084. Epub 2015 Oct 27.

Novel mechanism of ghrelin therapy for cachexia

Michiyoshi Hatanaka  1 , Masaaki Konishi  2 , Junnichi Ishida  2 , Masakazu Saito  2 , Jochen Springer  2
Affiliations

Novel mechanism of ghrelin therapy for cachexia

Michiyoshi Hatanaka et al. J Cachexia Sarcopenia Muscle. 2015 Dec.
No abstract available

PubMed Disclaimer

References

    1. Chen J-a, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumor- and cisplatin- induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6:132–143. - PMC - PubMed
    1. Sakaia H, Sagaraa A, Arakawa K, Sugiyama R, Hirosaki A, Takase K, et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicology and Applied Pharmacology. 2014;278:190–199. - PubMed
    1. Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329–337. - PMC - PubMed
    1. Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S, et al. Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle. 2013;4:334. Abstract 5–01.
    1. José M, Garcia RV, Boccia CD, Graham YY, Duus EM, Allen S, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–16. - PubMed

LinkOut - more resources